Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.

2.50
Hdl Handle:
http://hdl.handle.net/10033/621176
Title:
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.
Authors:
Ebensen, Thomas ( 0000-0001-8906-063X ) ; Debarry, Jennifer ( 0000-0002-3818-3768 ) ; Pedersen, Gabriel K; Blazejewska, Paulina; Weissmann, Sebastian; Schulze, Kai ( 0000-0003-2286-3416 ) ; McCullough, Kenneth C; Cox, Rebecca J; Guzmán, Carlos A
Abstract:
The need for more effective influenza vaccines is highlighted by the emergence of novel influenza strains, which can lead to new pandemics. There is a growing population of susceptible subjects at risk for severe complications of influenza, such as the elderly who are only in part protected by current licensed seasonal vaccines. One strategy for improving seasonal and pandemic vaccines takes advantage of adjuvants to boost and modulate evoked immune responses. In this study, we examined the capacity of the recently described adjuvant cyclic di-adenosine monophosphate (c-di-AMP) to serve as an adjuvant for improved mucosal influenza vaccines, and induce effective protection against influenza H5N1. In detail, c-di-AMP promoted (i) effective local and systemic humoral immune responses, including protective hemagglutination inhibition titers, (ii) effective cellular responses, including multifunctional T cell activity, (iii) induction of long-lasting immunity, and (iv) protection against viral challenge. Furthermore, we demonstrated the dose-sparing capacity of the adjuvant as well as the ability to evoke cross-clade protective immune responses. Overall, our results suggest that c-di-AMP contributes to the generation of a protective cell-mediated immune response required for efficacious vaccination against influenza, which supports the further development of c-di-AMP as an adjuvant for seasonal and pandemic influenza mucosal vaccines.
Affiliation:
Helmholtz Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Citation:
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. 2017, 8:1223 Front Immunol
Journal:
Frontiers in immunology
Issue Date:
2017
URI:
http://hdl.handle.net/10033/621176
DOI:
10.3389/fimmu.2017.01223
PubMed ID:
29033942
Type:
Article
Language:
en
ISSN:
1664-3224
Appears in Collections:
publications of the research group vaccinology and applied microbiology (VAC)

Full metadata record

DC FieldValue Language
dc.contributor.authorEbensen, Thomasen
dc.contributor.authorDebarry, Jenniferen
dc.contributor.authorPedersen, Gabriel Ken
dc.contributor.authorBlazejewska, Paulinaen
dc.contributor.authorWeissmann, Sebastianen
dc.contributor.authorSchulze, Kaien
dc.contributor.authorMcCullough, Kenneth Cen
dc.contributor.authorCox, Rebecca Jen
dc.contributor.authorGuzmán, Carlos Aen
dc.date.accessioned2017-11-15T13:53:29Z-
dc.date.available2017-11-15T13:53:29Z-
dc.date.issued2017-
dc.identifier.citationMucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice. 2017, 8:1223 Front Immunolen
dc.identifier.issn1664-3224-
dc.identifier.pmid29033942-
dc.identifier.doi10.3389/fimmu.2017.01223-
dc.identifier.urihttp://hdl.handle.net/10033/621176-
dc.description.abstractThe need for more effective influenza vaccines is highlighted by the emergence of novel influenza strains, which can lead to new pandemics. There is a growing population of susceptible subjects at risk for severe complications of influenza, such as the elderly who are only in part protected by current licensed seasonal vaccines. One strategy for improving seasonal and pandemic vaccines takes advantage of adjuvants to boost and modulate evoked immune responses. In this study, we examined the capacity of the recently described adjuvant cyclic di-adenosine monophosphate (c-di-AMP) to serve as an adjuvant for improved mucosal influenza vaccines, and induce effective protection against influenza H5N1. In detail, c-di-AMP promoted (i) effective local and systemic humoral immune responses, including protective hemagglutination inhibition titers, (ii) effective cellular responses, including multifunctional T cell activity, (iii) induction of long-lasting immunity, and (iv) protection against viral challenge. Furthermore, we demonstrated the dose-sparing capacity of the adjuvant as well as the ability to evoke cross-clade protective immune responses. Overall, our results suggest that c-di-AMP contributes to the generation of a protective cell-mediated immune response required for efficacious vaccination against influenza, which supports the further development of c-di-AMP as an adjuvant for seasonal and pandemic influenza mucosal vaccines.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleMucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalFrontiers in immunologyen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.